X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration aims to assess the anti-inflammatory and anti-fibrotic potential of RS BioTherapeutics’ lead compound, RSBT-001, an investigational semi-synthetic cannabidiolic acid complex, in a preclinical pulmonary fibrosis model.
Lead Product(s): Cannabidiolic Acid Complex
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: RSBT-001
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Institute on Alcohol Abuse and Alcoholism
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 29, 2023
Details:
Product characterization is an important next step for RSBT-001 before filing an Investigational New Drug (IND) application with the FDA for the treatment of chronic obstructive pulmonary disease (COPD).
Lead Product(s): RSBT-001
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: RSBT-001
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Recipharm AB
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership November 14, 2022
Details:
RSBT-001 is a patent-pending, nebulized, semi-synthetic, cannabidiolic acid complex in development to address exacerbation and prevent progression of both acute and chronic pulmonary inflammation related to respiratory diseases.
Lead Product(s): Cannabidiolic Acid Complex
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: RSBT-001
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Synthonics
Deal Size: $3.0 million Upfront Cash: Undisclosed
Deal Type: Financing September 26, 2022
Details:
The data from the proof-of-concept trial clearly indicates that RSBT-001, is a patent-pending, nebulized, semi-synthetic, cannabidiolic acid (CBDa) reduces cytokine level, and that this cytokine reduction is appropriately transient.
Lead Product(s): RSBT-001
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: RSBT-001
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Synthonics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 11, 2022
Details:
Under the license agreement with Synthonics, Inc. for the exclusive, worldwide right for RS BioTherapeutic's lead compound, RSBT-001, as both an alternative and a complement to corticosteroids for the treatment of chronic obstructive pulmonary disease (COPD).
Lead Product(s): RSBT-001
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: RSBT-001
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Synthonics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement May 23, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
